Oxitec is a British biotechnology company that develops genetically modified insects in order to improve public health and food security through insect control. The insects act as biological insecticides. The company claims that this technology is more effective and more environmentally friendly than chemical insecticides. The main principle behind Oxitec's mosquito control technology is release of genetically engineered male insects whose female offspring dies before reaching maturity.
History Oxitec was founded in 2002 as Oxford Insect Technologies in the United Kingdom by Luke Alphey and David Kelly, working with Oxford University's Isis Innovation technology transfer company. In August 2015, Oxitec was purchased by U.S.-based Intrexon for $160 million, and by US-based Third Security in early 2020. The company's first engineered insect was the pink bollworm (Pectinophora gossypiella). It was experimentally released in Arizona in 2006. The company then modified Aedes egyptii, a mosquito which spreads dengue fever, yellow fever, and chikungunya, followed by a series of field trials in multiple countries. Grey Frandsen was appointed CEO in 2017. He is an American who led start-up initiatives in the U.S. government and the private and non-profit sectors on matters relating to national and global public health security, biotechnology and crisis response. Frandsen led the company's transition to its 2nd generation technology in 2018. During the 2010s, Oxitec established partnerships with agricultural industry leaders and the Bill & Melinda Gates Foundation. Frandsen was named one of Malaria No More's 10-to-End innovators in 2019.
Genetically modified insects
Oxitec has developed genetically modified versions of A. aegypti mosquito and of P. gossypiella pink bollworm to be released in the wild with the goal of reducing existing insect populations. OX513A strain of A. aegypti mosquito developed by Oxitec produces a lethal transgene, which is only expressed in females. In a typical field application, male mosquitos carrying that transgene are released, and mate with wild females. The female offspring of these mosquitos dies before reaching maturity. This not only reduces the population, but also specifically prevents spread of diseases, which are transmitted through the bite of a female (males of this species do not bite). The male offspring can mate, further spreading the female-lethal gene. The introduction of the transgene into the population is self-limiting, as its frequency in the male population halves with each generation due to loss of females inheriting the gene. OX5034 males are therefore expected to effectively disappear from the population 10 generations after releases stop. The lethal transgene, tTAV, is a variant of the tetracyclin transactivator (tTA) gene optimized for expression in fruitflies and other insects. The original tTA gene was developed for research purposes as a fusion of an E.coli and a Herpes simplex virus genes. In the OX513A strain it is correctly expressed only in females, due to introduction of a female-specific RNA splicing module. A high concentration of the tTAV protein is lethal, likely due to interference with transcriptional regulation. Large numbers of transgenic mosquitos can be efficiently reared by temporarily suppressing the activity of the tTAV protein in females using tetracyclin family antibiotics. Variants of tTA are widely used in human cell lines and various model organism, including fungi, mice and plants, with no known adverse effects. OX513A also carry a fluorescent gene marker for easy screening of released mosquitos.
Projects
Grand Cayman The first field trials were performed on Grand Cayman, starting in 2009. Approximately 3.3 million transgenic male A. aegypti were released. The experiments demonstrated that the animals were able to survive in this environment and produce offspring. Some eleven weeks after the release, the observed A. aegypti population declined about 80%. The tests were deemed a scientific success, but criticism emerged over communication policy. In May 2016 Grand Cayman announced a program to use Oxitec mosquitoes. The first phase informed the community about the programme. The next phase treated an area with about 1,800 residents in West Bay. 88% fewer A. aegypti eggs were observed compared to an equivalent untreated area. In November 2018, the Cayman Islands government elected to cease any new field trial agreements with Oxitec, citing cost-benefit concerns with the technologies as the primary concern. Health Minister Dwayne Seymour and other legislators expressed skepticism on-the-record about the trials' effectiveness. However, Oxitec and the Mosquito Research and Control Unit of the Cayman Islands continue to analyze the data collected over the 10-year project.
… excerpt ends here. Continue reading the full article.
